Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California

@inproceedings{Lewnard2022ClinicalOA,
  title={Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California},
  author={Joseph A. Lewnard and Vennis Hong and M. Patel and Rebecca Kahn and Marc Lipsitch and Sara Y. Tartof},
  booktitle={medRxiv},
  year={2022}
}
Background: The Omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly achieved global dissemination, accounting for most infections in the United States by December 2021. Risk of severe outcomes associated with Omicron infections, as compared to earlier SARS-CoV-2 variants, remains unclear. Methods: We analyzed clinical and epidemiologic data from cases testing positive for SARS-CoV-2 infection within the Kaiser Permanente Southern California healthcare system from November 30, 2021 to January… 
Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2)
TLDR
Omicron was associated with a 75% risk reduction of hospitalization compared with Delta (B.617.2) and reduced length of hospital stay and the length of stay in hospital for Omicron (BA.1) patients was significantly shorter than for Delta (confounding-adjusted difference).
Omicron (BA.1) SARS-CoV-2 Variant Is Associated With Reduced Risk of Hospitalization and Length of Stay Compared With Delta (B.1.617.2)
TLDR
The reduction in the risk of hospitalization for Omicron (BA.1.1) and Delta (B.617.2) SARS-CoV-2 patients is consistent with a risk reduction of a similar magnitude, and a confounding-adjusted HR lower than HR 0.25 (95%CI 0.15 to 0.43) for confounders is consistent.
Serious hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants: an exposed-unexposed cohort study in December 2021 from the COVID-19 surveillance databases in France
TLDR
This study confirms the lower severity of Omicron and the vaccine protection is essential in the elderly as they have a high risk of severe hospital events following infection with Omicrons, even if much this risk is lower than with Delta.
Risk of COVID-19 related deaths for SARS-CoV-2 Omicron (B.1.1.529) compared with Delta (B.1.617.2)
TLDR
The results support early work showing the relative reduction in severity of Omicron compared to Delta in terms of hospitalisation and extends this research to assess COVID-19 mortality.
Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
TLDR
COVID-19 disease severity appears to be lower during the Omicron period than during previous periods of high transmission, likely related to higher vaccination coverage,† which reduces disease severity, lower virulence, and infection-acquired immunity.
...
...

References

SHOWING 1-10 OF 29 REFERENCES
Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa
TLDR
Assessment of clinical severity of individuals infected with Omicron in South Africa suggests a reduced risk of hospitalisation among SGTF-infected individuals when compared to non-SGTF infected individuals in the same time period, and a reduction of severe disease whenCompared to earlier Delta infections.
Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron
TLDR
First time SARS-CoV-2 infections occurring at a time when the Omicron variant was rapidly spreading were associated with significantly less severe outcomes than first-time infections when the Delta variant predominated.
Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa
TLDR
Analysis of routine surveillance data from South Africa suggests that, in contrast to the Beta and Delta, the Omicron variant of SARS-CoV-2 demonstrates substantial population-level evidence for evasion of immunity from prior infection.
Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada
TLDR
In Ontario, hospitalization and death associated with Omicron, as compared to matched cases infected with Delta, was examined in a matched cohort study, considering time to hospitalization or death as the outcome, and analyzed with a Cox proportional hazards model.
Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant
TLDR
Protection afforded by prior infection in preventing symptomatic reinfection with Alpha, Beta, or Delta is robust, at about 90%, while such protection against reinfections with Omicron is lower, it is still considerable at nearly 60%.
The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
TLDR
In hamsters that had been infected with the omicron variant, a 3 log10 lower viral RNA load was detected in the lungs as compared to animals infected with D614G and no infectious virus was detectable in this organ.
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
TLDR
Primary immunisation with two BNT162b2 or ChAdOx1 doses provided no or limited protection against symptomatic disease with the Omicron variant, and Boosting with BNT 162b2 following either primary course significantly increased protection.
Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
TLDR
VE of 3 mRNA-1273 doses against infection with delta was high and durable, but VE against omicron infection was lower, including among immunocompromised individuals.
SARS-CoV-2 Omicron variant replication in human respiratory tract ex vivo
TLDR
It is shown that Omicron replicated faster than all other SARS-CoV-2 in the bronchus but less efficiently in the lung parenchyma, and this likely contributes to its inherently higher transmissibility, irrespective of its ability to evade antibody immunity.
...
...